scholarly journals COVID-19 Vaccine Effectiveness by Product and Timing in New York State

2021 ◽  
Author(s):  
Eli Rosenberg ◽  
Vajeera Dorabwila ◽  
Delia Easton ◽  
Ursula Bauer ◽  
Jessica Kumar ◽  
...  
Keyword(s):  
New York ◽  
New York State ◽  
Population Based ◽  
Incidence Rates ◽  
Vaccine Effectiveness ◽  
Statewide Testing ◽  
Waning Immunity ◽  
Incident Laboratory ◽  
A Prospective Study ◽  
Monthly Incidence

Background: US population-based data on COVID-19 vaccine effectiveness (VE) for the 3 currently FDA- authorized products is limited. Whether declines in VE are due to waning immunity, the Delta variant, or other causes, is debated. Methods: We conducted a prospective study of 8,834,604 New York adults, comparing vaccine cohorts defined by product, age, and month of full-vaccination to age-specific unvaccinated cohorts, by linking statewide testing, hospital, and vaccine registry databases. VE was estimated from May 1, 2021 for incident laboratory-confirmed COVID-19 cases (weekly life-table hazard rates through September 3) and hospitalizations (monthly incidence rates through August 31). Results: 155,092 COVID-19 cases and 14,862 hospitalizations occurred. Estimated VE for cases declined contemporaneously across age, products, and time-cohorts, from high levels beginning May 1 (1.8% Delta variant prevalence), to a nadir around July 10 (85.3% Delta), with limited changes thereafter (>95% Delta). Decreases were greatest for Pfizer-BioNTech (-24.6%, -19.1%, -14.1% for 18-49, 50-64 years, and ≥65 years, respectively), and similar for Moderna (-18.0%, -11.6%, -9.0%, respectively) and Janssen (-19.2%, -10.8, -10.9%, respectively). VE for hospitalization for adults 18-64 years was >86% across cohorts, without time trend. Among persons ≥65 years, VE declined from May to August for Pfizer-BioNTech (95.0% to 89.2%) and Moderna (97.2% to 94.1%). VE was lower for Janssen, without trend, ranging 85.5%-82.8%. Conclusions: Declines in VE for cases may have been primarily driven by factors other than waning. VE for hospitalizations remained high, with modest declines limited to Pfizer-BioNTech and Moderna recipients ≥65 years, supporting targeted booster dosing recommendations.

scholarly journals LUNG CANCER INCIDENCE IN VARIOUS CITIES OF THE WORLD (REVIEW)

2020 ◽  
Vol 66 (3) ◽  
pp. 239-246
Author(s):  
Liliya Zhuykova ◽  
Yevgeniy Choynzonov ◽  
Olga Ananina ◽  
Nina Lyakhova ◽  
Lidiya Pikalova
Keyword(s):  
Lung Cancer ◽  
New York ◽  
New York City ◽  
Cancer Incidence ◽  
Rural Areas ◽  
Urban Areas ◽  
New York State ◽  
Incidence Rates ◽  
Lung Cancer Incidence ◽  
Cancer Incidence Rates

Apart from smoking, an urban factor is an established risk factor for lung cancer. Lung cancer is associated with environmental factors, occupational exposure, bad habits and lifestyle factors. Approximately 17% of the annual deaths from lung cancer among adults are attributable to exposure to carcinogens located in the surface layer of the urban atmosphere, with industrial pollution and occupational hazards. According to recent data, 97% of cities in low- and middle-income countries with a population of more than 100 thousand people do not meet WHO recommendations for air quality; in high-income countries, this figure has been reduced to 49%. In the United States, the studies demonstrated that the prevalence of combined lung cancer was higher in urban areas (10.2%) than in rural areas (4.8%). There was a difference in the lung cancer incidence rates between the populations of the New York City and the New York State. In males, the lung cancer incidence rates were 1.4 times higher in the New York City than in the New York State (68.9 ± 1.2 0/0000 versus 48.5 ± 0.2 0/0000). In females, the lung cancer incidence rates were 1.2 times higher in the New York City than in the New York State (43.0 ± 0.3 and 34.9 ± 0.1 0/0000, respectively). In China, in urban areas, the lung cancer incidence mortality rates were 36.6 0/0000 and 28.9 0/0000, respectively. In rural areas, the corresponding values were 33.4 and 26.6 0/0000, respectively. Although the lung cancer incidence and mortality rates are higher in urban areas than in rural areas, these differences are gradually decreasing: the incidence rate between urban and rural areas has decreased from 2.1 to 1.1. The issue of the impact of environment on the incidence of lung cancer is challenging. The outdoor environment affects people’s health with varying degrees of intensity both in time and in space.

scholarly journals 2625. Incidence of Bronchiolitis Requiring Hospitalization in the First 2 years of Life Among Healthy Term Infants with Different Races/Ethnicities: A Population-based Longitudinal Study

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S914-S915
Author(s):  
Kengo Inagaki ◽  
Chad Blackshear ◽  
Charlotte V Hobbs
Keyword(s):  
New York ◽  
Socioeconomic Status ◽  
Proportional Hazards ◽  
New York State ◽  
Multivariable Analysis ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Indigenous Populations ◽  
Term Infants ◽  
Race Ethnicity

Abstract Background Race/ethnicity is currently not considered a risk factor for bronchiolitis, except for indigenous populations in western countries. We sought to determine the incidence of hospitalization with bronchiolitis among different races/ethnicities, because such information can lead to more tailored preventive care. Methods We performed a population-based longitudinal observational study using the State Inpatient Database from New York state. Infants born between 2009 and 2013 at term without comorbidities were followed for the first 2 years of life, up to 2015. We calculated incidence among different race/ethnicity groups, and evaluated risks by developing Cox proportional hazards regression models. Results Of 877,465 healthy term infants, 10 356 infants were hospitalized with bronchiolitis. Overall, incidence was 11.8 per 1,000 births. Substantial difference in infants born in different seasons was observed (Figure 1). The incidence in non-Hispanic white, non-Hispanic black, Hispanic, and Asian infants was 8.6, 15.4, 19.1, and 6.5 per 1,000 births, respectively (table). On multivariable analysis adjusting for socioeconomic status, the risks remained substantially high among non-Hispanic black (hazard ratio [HR] 1.42, 95% confidence interval [CI]: 1.34–1.51) and Hispanic infants (HR 1.77, 95% CI: 1.67–1.87), particularly beyond 2–3 months of age, whereas Asian race was protective (HR 0.62, 95% CI: 0.56–0.69) (Figure 2, 3). Conclusion The risks of bronchiolitis hospitalization in the first 2 years of life was substantially higher among infants with non-Asian minority infants, particularly beyond 2–3 months of age. Further research efforts to identify effective public health interventions in each race/ethnic groups with varied socioeconomic status, such as improvement in access to care and anticipatory guidance, is warranted to overcome health disparity. Disclosures All authors: No reported disclosures.

scholarly journals Infertility treatment and autism risk using the Modified Checklist for Autism in Toddlers (M-CHAT)

2020 ◽  
Vol 35 (3) ◽  
pp. 684-693 ◽  
Author(s):  
S L Robinson ◽  
T Parikh ◽  
T Lin ◽  
E M Bell ◽  
E Heisler ◽  
...  
Keyword(s):  
New York ◽  
Study Design ◽  
Screening Tool ◽  
New York State ◽  
Population Based ◽  
Infertility Treatment ◽  
Autism Spectrum ◽  
Fertility Treatment ◽  
York State

Abstract STUDY QUESTION Are toddlers conceived by fertility treatment at higher risk of failing a screening tool for autism spectrum disorders (ASD) than toddlers not conceived by treatment? SUMMARY ANSWER Compared with children not conceived by infertility treatment, children conceived by any infertility treatment, ovulation induction with or without intrauterine insemination (OI/IUI), or assisted reproductive technologies (ART) appeared to have had higher odds of failing an ASD screening; however, results were inconclusive and need replication. WHAT IS KNOWN ALREADY Although most of the studies which have examined risk of ASD after ART show no association, the results are mixed. Thus, further studies are needed to clarify this association. STUDY DESIGN SIZE, DURATION The Upstate KIDS Study is a population-based, prospective cohort study of children born in New York State between 2008 and 2010. Children were screened for ASD using the Modified Checklist for Autism in Toddlers (M-CHAT) at ages 18 and 24 months. PARTICIPANTS/MATERIALS, SETTING, AND METHODS The New York State live-birth registry was used to identify newborns conceived with and without fertility treatment with a 1:3 ratio, frequency matched on region of birth. At 18 and 24 months, 3183 and 3063 mothers, respectively, completed the M-CHAT questionnaire. The current analysis included 2586 singletons and 1296 twins with M-CHAT information at 18 and/or 24 months. Multivariable logistic regression with generalized estimating equations (GEE) was used to estimate odds ratios (aOR) and 95% confidence intervals (CI) after adjustment for covariates such as maternal age, education and plurality. MAIN RESULTS AND THE ROLE OF CHANCE We found that 200 (5.2%) and 115 (3.0%) children failed the M-CHAT at 18 and 24 months, respectively. The associations between use of infertility treatment and failing the M-CHAT at 18 and/or 24 months were positive but inconclusive as they failed to exclude no association (18 months aOR 1.71, 95% CI: 0.81–3.61; 24 months aOR 1.78, 95% CI: 0.66–4.81; and both 18 and 24 months aOR 1.53, 95% CI: 0.78–2.99). The relationships between OI/IUI and ART with M-CHAT failure at 18 and/or 24 months were similar to those of using any fertility treatment. In vitro fertilization with intracytoplasmic sperm injection was not consistently positively or inversely associated with M-CHAT failure at each time point (18 months aOR 1.20, 95% CI: 0.51–2.83; 24 months aOR 0.93, 95% CI: 0.37–2.31; and both 18 and 24 months aOR 1.09, 95% CI: 0.50–2.60). LIMITATIONS REASONS FOR CAUTION The M-CHAT is a screening tool used for ASD risk assessment, and therefore, M-CHAT failure does not indicate ASD diagnosis. In addition, we did not have power to detect associations of small magnitude. Finally, non-response to follow-up may bias the results. WIDER IMPLICATIONS OF THE FINDINGS Despite lack of precision, the positive associations between ART and M-CHAT failure suggest that larger population-based studies with longer follow-up are needed. STUDY FUNDING/COMPETING INTEREST(S) Supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD; contracts HHSN275201200005C, HHSN267200700019C). The sponsor played no role in the study design, data collection, data analysis or interpretation, writing of the manuscript or decision to submit the article for publication. There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER Not applicable.

scholarly journals Pilot study of population-based newborn screening for spinal muscular atrophy in New York state

2017 ◽  
Vol 20 (6) ◽  
pp. 608-613 ◽  
Author(s):  
Jennifer N Kraszewski ◽  
Denise M Kay ◽  
Colleen F Stevens ◽  
Carrie Koval ◽  
Bianca Haser ◽  
...  
Keyword(s):  
New York ◽  
Pilot Study ◽  
Spinal Muscular Atrophy ◽  
Newborn Screening ◽  
Muscular Atrophy ◽  
New York State ◽  
Population Based ◽  
York State

A population-based survey of sun lamp and tanning parlor use in New York State, 1990

1994 ◽  
Vol 31 (3) ◽  
pp. 510-512 ◽  
Author(s):  
Patricia P. Lillquist ◽  
Mark S. Baptiste ◽  
Melissa A. Witzigman ◽  
Philip C. Nasca
Keyword(s):  
New York ◽  
New York State ◽  
Population Based ◽  
York State ◽  
Population Based Survey

scholarly journals The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-based Study over 20 Years

2017 ◽  
Vol 45 (4) ◽  
pp. 574-579 ◽  
Author(s):  
Mohanad M. Elfishawi ◽  
Nour Zleik ◽  
Zoran Kvrgic ◽  
Clement J. Michet ◽  
Cynthia S. Crowson ◽  
...  
Keyword(s):  
New York ◽  
Population Based ◽  
Incidence Rates ◽  
Comorbid Conditions ◽  
Population Based Study ◽  
Significant Public Health ◽  
Public Health Challenge ◽  
Rising Incidence ◽  
Adjusted Incidence ◽  
Incident Cases

Objective.To examine the incidence of gout over the last 20 years and to evaluate possible changes in associated comorbid conditions.Methods.The medical records were reviewed of all adults with a diagnosis of incident gout in Olmsted County, Minnesota, USA, during 2 time periods (January 1, 1989–December 31, 1992, and January 1, 2009–December 31, 2010). Incident cases had to fulfill at least 1 of 3 criteria: the American Rheumatism Association 1977 preliminary criteria for gout, the Rome criteria, or the New York criteria.Results.A total of 158 patients with new-onset gout were identified during 1989–1992 and 271 patients during 2009–2010, yielding age- and sex-adjusted incidence rates of 66.6/100,000 (95% CI 55.9–77.4) in 1989–1992 and 136.7/100,000 (95% CI 120.4–153.1) in 2009–2010. The incidence rate ratio was 2.62 (95% CI 1.80–3.83). At the time of their first gout flare, patients diagnosed with gout in 2009–2010 had higher prevalence of comorbid conditions compared with 1989–1992, including hypertension (69% vs 54%), diabetes mellitus (25% vs 6%), renal disease (28% vs 11%), hyperlipidemia (61% vs 21%), and morbid obesity (body mass index ≥ 35 kg/m2; 29% vs 10%).Conclusion.The incidence of gout has more than doubled over the recent 20 years. This increase together with the more frequent occurrence of comorbid conditions and cardiovascular risk factors represents a significant public health challenge.

The impact of age and gender on the incidence of glial tumors in New York state from 1976–1995

2000 ◽  
Vol 93 (6) ◽  
pp. 932-939 ◽  
Author(s):  
Brian P. McKinley ◽  
Arthur M. Michalek ◽  
Robert A. Fenstermaker ◽  
Robert J. Plunkett
Keyword(s):  
New York ◽  
New York State ◽  
Incidence Rates ◽  
Female Population ◽  
Glial Tumors ◽  
Content Type ◽  
York State ◽  
Adjusted Incidence ◽  
Age And Sex ◽  
Fine Print

Object. In this study the authors describe secular trends in the incidence of three glial tumors—glioblastoma multiforme (GBM), astrocytoma not otherwise specified (ANOS), and anaplastic astrocytoma (AA)—in New York state from 1976 through 1995. They also describe the effect of age and sex on the relative risk (RR) for these tumors, specifically GBM.Methods. Crude, age-, and sex-specific incidence rates were calculated for each tumor type from 1976 to 1995 by using data from the New York State Cancer Registry. Age-adjusted incidence rates were calculated by the direct standardization procedure, in which the 1970 United States Census Population Standard Million is used. The RR of GBM for the female population was calculated and plotted. Statistical comparisons were made using Pearson's correlation coefficient and regression analysis with the coefficient of variation.Conclusions. The age-adjusted incidence of these three glial tumors increased during the study period. Increases in age-specific incidence of GBM were primarily limited to patients 60 years of age or older. The reasons for these increases cannot be fully explained with the data. Those in the female population had a lower risk of developing these tumors than those in the male. For GBM, the protective effect of sex was first evident at the approximate age of menarche, was greatest at the approximate age of menopause, and decreased in postmenopausal age strata. The overall protective effect of female sex and the described trend in RR for GBM in the female population suggests that sex hormones and/or genetic differences between males and females may play a role in the pathogenesis of this tumor.

scholarly journals Use and risks of surgical mesh for pelvic organ prolapse surgery in women in New York state: population based cohort study

BMJ ◽  
2015 ◽  
Vol 350 (jun02 1) ◽  
pp. h2685-h2685 ◽  
Author(s):  
B. Chughtai ◽  
J. Mao ◽  
J. Buck ◽  
S. Kaplan ◽  
A. Sedrakyan
Keyword(s):  
New York ◽  
Cohort Study ◽  
Pelvic Organ Prolapse ◽  
Surgical Mesh ◽  
New York State ◽  
Pelvic Organ ◽  
Population Based ◽  
Prolapse Surgery ◽  
York State ◽  
State Population

The New York Angler Cohort Study: Exposure Characterization and Reproductive and Developmental Health

1996 ◽  
Vol 12 (3-4) ◽  
pp. 327-334 ◽  
Author(s):  
John E. Vena ◽  
Germaine M. Buck ◽  
Paul Kostyniak ◽  
Pauline Mendola ◽  
Edward Fitzgerald ◽  
...  
Keyword(s):  
New York ◽  
Breast Milk ◽  
New York State ◽  
Population Based ◽  
York State ◽  
Entire Cohort ◽  
Telephone Interviews ◽  
Current Consumption ◽  
Other Substances ◽  
Developmental Health

The New York State Angler Study will evaluate the association between past and current consumption of contaminated fish from Lake Ontario and both short- and long-term health effects in a population-based cohort. It will measure fish consumption and reproductive and developmental health among 10,518 male anglers and 6,651 of their wives or partners, as well as among 913 female anglers. To characterize exposure among subgroups of the cohort, further analytical methods were developed and implemented to measure specific polychlorinated biphenyls (PCB) congeners, methylmercury, and other substances in biological samples. Exposure assessment has been completed for a stratified random sample of 321 anglers. In addition, analyses for 79 congeners of PCBs are complete for 177 anglers. A special study of duck andturtle consumers currently is underway. Telephone interviews have been completed with 2,454 of the 2,999 women who planned a pregnancy between 1991 and 1994. The entire cohort of male anglers, partners of male anglers, and female anglers has been submitted for matching with the New York State live birth and fetal death registries to obtain lifetime reproductive histories. A medical record abstraction study will assess perinatal and developmental outcomes among the 3,442 births that occurred between 1986 and 1991. Finally, a study of breast milk from currently lactating women is underway, and 215 breast milk samples have been collected from the planned pregnancy subcohort. Progress on each of the study components is discussed herein.

Sign in / Sign up

Export Citation Format

Share Document